CAMBRIDGE, Mass.--(BUSINESS WIRE)--Curis, Inc. (NASDAQ: CRIS), a drug development company seeking to develop proprietary targeted medicines for cancer treatment, today announced that the Company will release its fourth quarter financial results on Tuesday, February 10, 2009 before the market opens. The Company will also hold a conference call on the same day at 9:00 A.M. Eastern time to discuss: (i) its Hedgehog pathway inhibitor program under collaboration with Genentech, (ii) CUDC-101, CUDC-305 and other proprietary targeted cancer programs, (iii) its financial results as of and for the fourth quarter and fiscal year ended December 31, 2008, and (iv) additional corporate activities. Daniel Passeri, President and Chief Executive Officer of Curis, will host the call.
